InterMune Company Profile - Aug 24, 2011 by WrightReports

VIEWS: 887 PAGES: 13

More Info
									Company Fundamentals\Company Profile

   A Wright Investors' Service Research Report:

   InterMune, Inc.
                                                                                      440 Wheelers Farms Road
                                                                                      Milford, CT 06461 U.S.A.


  COMPANY PROFILE
  Figures in U.S. Dollars

                                 Wright Quality Rating:BBNN                               Key Data

   InterMune, Inc. (InterMune) is a biopharmaceutical company focused on developing       Ticker:
   and commercializing therapies in pulmonology and hepatology. As of December 31,        ITMN
   2010, the Company had rights to one approved and marketed product, Actimmune,
   which is approved in the United States and numerous other countries for the            2010 Sales:
   treatment of chronic granulomatous disease (CGD) and severe, malignant
                                                                                          26,991,000
   osteopetrosis. In addition, the Company has an advanced-stage product candidate,
   pirfenidone, in pulmonology. As of December 31, 2010, the Company also had a
   hepatology portfolio of small molecule compounds that were in pre-clinical research.   Major Industry:
   The Company is focusing on the treatment of idiopathic pulmonary fibrosis (IPF) and    Drugs, Cosmetics & Health
   chronic hepatitis C (HCV) viral infection. In January 2010, the FDA accepted its New   Care
   Drug Application (NDA) for pirfenidone for the treatment of patients with mild to
   moderate IPF and granted priority review status for its NDA.                      Sub Industry:
                       Stock Chart                               Officers            Ethical Drug Manufacturers
                                                         Chairman, President & Chief
                                                                Executive            Country:
                                                               Daniel G. Welch       United States

                                                            Senior Vice President         Currency:
                                                          Finance & Chief Financial
                                                                                          U.S. Dollars
                                                                   Officer
                                                              John C. Hodgman
                                                                                          Fiscal Year Ends:
                                                           Senior Vice President,         December
                                                        Secretary & General Counsel
                                                             Robin J. Steele Esq.   Employees
                                                                                    105

                                                                                          Exchanges:
                                                                                          NAS

                                            
								
To top